Unknown

Dataset Information

0

Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma.

ABSTRACT: Radiofrequency ablation (rfa) is a standard treatment for small, unresectable hepatocellular carcinomas (hccs). However, rfa for larger tumours is less successful, and intravenous lyso-thermosensitive liposomal doxorubicin during rfa is one technique postulated to potentially address that limitation. This drug-plus-device combination therapy was used to completely treat a hcc in a patient who underwent liver transplantation 79 days later.

SUBMITTER: Hong CW 

PROVIDER: S-EPMC3671035 | biostudies-literature | 2013 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Liposomal doxorubicin plus radiofrequency ablation for complete necrosis of a hepatocellular carcinoma.

Hong C W CW   Libutti S K SK   Wood B J BJ  

Current oncology (Toronto, Ont.) 20130601 3

Radiofrequency ablation (rfa) is a standard treatment for small, unresectable hepatocellular carcinomas (hccs). However, rfa for larger tumours is less successful, and intravenous lyso-thermosensitive liposomal doxorubicin during rfa is one technique postulated to potentially address that limitation. This drug-plus-device combination therapy was used to completely treat a hcc in a patient who underwent liver transplantation 79 days later. ...[more]

Similar Datasets

Unknown Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation.
| S-EPMC7654834 | biostudies-literature
Unknown Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies.
| S-EPMC3264789 | biostudies-literature
Unknown Radiofrequency ablation plus nucleotide analogous for hepatitis B virus-related hepatocellular carcinoma: a cost-effectiveness analysis.
| S-EPMC6129532 | biostudies-other
Unknown RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma.
| S-EPMC6095431 | biostudies-literature
Unknown Combination radiofrequency ablation and intravenous radiolabeled liposomal Doxorubicin: imaging and quantification of increased drug delivery to tumors.
| S-EPMC2858812 | biostudies-literature
Unknown Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status.
| S-EPMC4686130 | biostudies-literature
Transcriptomics Transcriptomics characterization of hepatocellular carcinoma (HCC) after incomplete radiofrequency ablation (iRFA)
2022-09-05 | GSE212604 | GEO
Unknown Radiofrequency ablation for hepatocellular carcinoma: 10-year outcome and prognostic factors.
| S-EPMC3321437 | biostudies-literature
Transcriptomics N7-Methylguanosine tRNA modification promotes hepatocellular carcinoma metastasis after insufficient radiofrequency ablation
2022-11-20 | GSE199966 | GEO
Unknown Local modalities for inoperable hepatocellular carcinoma: radiofrequency ablation versus stereotactic body radiotherapy.
| S-EPMC6291538 | biostudies-literature